Headlines about Shire (NASDAQ:SHPG) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Shire earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.4885690740959 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s rankings:

SHPG has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $222.00 target price on shares of Shire in a research note on Monday, August 21st. Royal Bank Of Canada set a $213.00 target price on Shire and gave the company a “buy” rating in a research note on Friday, August 4th. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Shire in a research note on Sunday, October 8th. FBR & Co started coverage on Shire in a report on Thursday, October 19th. They issued a “buy” rating and a $201.00 price target on the stock. Finally, ValuEngine upgraded Shire from a “hold” rating to a “buy” rating in a report on Thursday, October 26th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $212.18.

Shire (NASDAQ:SHPG) traded down $1.92 during trading hours on Friday, reaching $147.86. The company’s stock had a trading volume of 418,603 shares, compared to its average volume of 1,306,277. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $44,997.96, a price-to-earnings ratio of 10.30, a price-to-earnings-growth ratio of 0.83 and a beta of 1.60. Shire has a 12-month low of $137.17 and a 12-month high of $192.15.

Shire (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter. Shire had a return on equity of 14.41% and a net margin of 10.95%. Shire’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.17 EPS. equities research analysts forecast that Shire will post 15 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Shire (SHPG) Share Price” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-shire-shpg-share-price/1726326.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Insider Buying and Selling by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.